High Potency Active Pharmaceutical Ingredients (HPAPI) are a specialized market segment in the pharmaceutical industry, but it is the fastest growing market segment. The API is classified as HPAPI and its occupational exposure limit is equal to or less than 10 micrograms per cubic meter of air. Statistic
The global high potency active pharmaceutical ingredients market had a valuation of US$ 21.165 million in 2020, and is projected to attain US$ 40,983.82 million by the end of 2027.
Get a Sample Copy of the Report 2021 @
During the forecast period, the increase in the prevalence of cancer is expected to drive the growth of the global high potency active pharmaceutical ingredients market. According to the American Cancer Society, in 2019, there will be an estimated 1,762,450 newly diagnosed cancer cases and 606,880 deaths from cancer in the U.S. in 2019. In addition, the development of antibody-drug conjugates is also expected to help the global high potency active pharmaceutical ingredients market. In June 2018, GlaxoSmithKline began a randomized study to evaluate the effectiveness and safety of the GSK2857916 antibody-drug conjugate in multiple myeloma participants. In December 2019, the company announced that it would submit the test data to the U.S. Food and Drug Administration (FDA) for review and approval.
Innovative molecular sector dominates the global high potency active pharmaceutical ingredients market in 2019, with a value share of 70.3%, followed by generic drugs.
The conservative approach to accepting new and expensive drugs is expected to hamper the growth of the global high potency active pharmaceutical ingredients market. Both patients and doctors avoid trying new products launched on the market.
Due to patient and physician preference patterns, market penetration will initially have a large impact; however, when the product is established in the market, its impact in the future will be small. In the current circumstances, highly effective active pharmaceutical ingredients are a new technology, and it will take time to occupy the market, so it will become a limiting factor for the development and growth of the global high potency active pharmaceutical ingredients market.
In addition, significant capital investment in the research and development of highly effective active pharmaceutical ingredients is also expected to limit the growth of the global high potency active pharmaceutical ingredients market.
Measures to address the challenges of the high-efficiency active pharmaceutical ingredient industry are expected to provide market participants with profitable growth opportunities. In February 2020, the high-efficiency active pharmaceutical ingredient conference to be held in London in May 2020 will be announced to discuss the challenges faced by the high-efficiency active pharmaceutical ingredient industry.
It is expected that an increasing number of solid oral drug production facilities will also contribute to market growth. In September 2020, Piramal Pharma Solutions held a grand opening at its recently acquired solid oral medicine manufacturing plant in Sellersville, Pennsylvania.
The global high potency active pharmaceutical ingredients market in 2019 is US$ 19,258.8 million, and it is expected to reach US$ 40,983.82 billion in 2027, with a compound annual growth rate of 9.9. In 2020 and 2027.
Ask for PDF sample copy of the report @
The main players in the global high potency active pharmaceutical ingredients market are focused on expanding their production capacity to increase their market share. In September 2020, MilliporeSigma announced that it would spend $ 65 million to expand manufacturing capacity and production capacity of high-efficiency active pharmaceutical ingredients and ADCs at its factory near Madison, Wisconsin.
To increase their market share, major companies in the industry are focusing on partnership and cooperation tactics. Piramal Pharma Solutions announced in July 2020 that it will deliver both the BDC-1001 ISAC drug ingredient and the medication product for Bolt Biotherapeutics’ current Phase 1/2 clinical research in cancer patients.
Key companies contributing in the global high potency active pharmaceutical ingredients market are Teva Pharmaceutical Industries Ltd., Roche Diagnostics, Pfizer Inc., Eli Lilly and Company, Bayer AG, SEQENS, BASF AG, Carbogen Amcis AG, Novartis International AG, Lonza, Sanofi Aventis, Minakem, Cambrex Corporation, SEQENS, Ajinomoto Bio-Pharma Services, MilliporeSigma, Merck & Co., Covidien Plc., Boehringer Ingelheim, and Bristol-Myers Squibb.
The main participants in the global high potency active pharmaceutical ingredients market are focusing on broadening their production capacity to increase their market share. In August 2020, Ajinomoto Biopharmaceutical Services Co., Ltd. added a new production facility in Visakhapatnam, India, expanding small molecule manufacturing capacity.
Similarly, in April 2019, Cambrex Corporation completed construction of a $ 24 million high-efficiency active pharmaceutical ingredient manufacturing facility at its facility in Charles City, Iowa.
Reasons to Purchase this Report
• To gain an in-depth understanding of High Potency Active Pharmaceutical Ingredients market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, High Potency Active Pharmaceutical Ingredients market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Buy This Complete A Business Report With Flat US $2000 Off @
Table of Content
Global High Potency Active Pharmaceutical Ingredients Market Research Report
Section 1: Global High Potency Active Pharmaceutical Ingredients Industry Overview
Section 2: Global Economic Impact on High Potency Active Pharmaceutical Ingredients Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: High Potency Active Pharmaceutical Ingredients Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global High Potency Active Pharmaceutical Ingredients Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027